Document is current
Any future updates will be listed below
-
Authors
Xu, Edward
Vanghelof, Joseph
Wang, Yiyang
Patel, Anisha
Furst, Jacob
Raicu, Daniela Stan
Neumann, Johannes Tobias
Wolfe, Rory
Gao, Caroline X.
McNeil, John J.
Shah, Raj C.
Tchoua, Roselyne
-
Funding
Funding for this research was provided by:
National Institutes of Health (NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389, NIA U19AG062682, UL1TR002389)
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 14 June 2024
First Online: 23 July 2024
Change Date: 23 August 2024
Change Type: Update
Change Details: The presentation of tables 1 and 2 were adjusted.
Declarations
:
: The ASPREE-XT study which included analyses of data from the ASPREE clinical trial was approved by the University of Iowa Institutional Review Board. Informed consent was obtained for all participants.
: Not applicable.
: The authors declare no competing interests.
